2021 Digital Health Drug Development 
Digital Health Global
NOVEMBER 12, 2024
The company’s decline Since its peak valuation of $6 billion in 2021, 23andMe’s share price has plunged by 99%. 23andMe tried to monetize its extensive genetic database by collaborating with pharmaceutical companies for drug research. As the consumer DNA testing market has matured, growth has slowed.
Healthcare IT Today
MARCH 3, 2025
The CRO industry has remained stagnant with extremely limited adoption of technology or modern approaches to streamline clinical development. From 2021 to 2022 alone, the cost of developing a single drug was estimated to have increased by almost $300M.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
JANUARY 25, 2024
Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism. Debiopharm’s main activities include drug development, drug manufacturing and digital health investment.
Digital Health Global
SEPTEMBER 28, 2023
The new seed funding activity will therefore pave the way for the next generation of treatments and digital health, providing healthcare professionals with better tools to improve experiences and outcomes for patients. Since 2017 Debiopharm has invested in 15 AI and digital health companies, typically leading the investment rounds.
Digital Health Global
JUNE 2, 2024
About Massive Bio: Massive Bio’s vision is to cover entire Pharma value chain with disruptive solutions to improve entire ecosystem from drug development to commercialization. ASCO 2021 Meeting Abstract. Accessed on October 28, 2021. Oncology Network community practices. Available online at: [link].
Society for Participatory Medicine
JANUARY 27, 2022
Clinical trials, care encounters, and access to data were found guilty of not meeting patients where they are and not adequately addressing the social determinant of health factors, creating barriers for patients. Market forces drove acceleration in digital health, specifically telemedicine, which were sorely needed for several years.
Xealth
JUNE 27, 2023
David Slifka, Vice President, Commercial Enablement The digital health ecosystem is a complex place. Confusion abounds among healthcare providers regarding digital therapeutics (DTx) terminology and classifications, and understandably so. DTx fall within the digital medicine subset within the larger digital health ecosystem.
Expert insights. Personalized for you.
88 
Let's personalize your content